These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 10286432)
21. More states adopt generic substitution laws. Goldsmith LS J Leg Med (N Y); 1977 Oct; 5(10):31-2. PubMed ID: 303272 [No Abstract] [Full Text] [Related]
22. States moving to allow generic substitution. Internist; 1979 May; 20(4):12-3. PubMed ID: 10242129 [No Abstract] [Full Text] [Related]
23. Bioequivalence/bioavailability retention samples. Ransom C Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218 [No Abstract] [Full Text] [Related]
24. Benefits and liabilities of generic prescribing. Lee AM W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384 [No Abstract] [Full Text] [Related]
25. Prescriptions enter the political arena. Regier H J Leg Med (N Y); 1974; 2(2):24-30. PubMed ID: 4545342 [No Abstract] [Full Text] [Related]
26. Bolar agrees to guilty plea in generic drug probe. Wagner M Mod Healthc; 1991 Mar; 21(9):17. PubMed ID: 10109180 [No Abstract] [Full Text] [Related]
27. What's in a name? Generic vs brand name drugs. Levin AA Health PAC Bull; 1986 Jun; 16(5):37, 39. PubMed ID: 10276741 [No Abstract] [Full Text] [Related]
28. Generic drugs. Med Lett Drugs Ther; 1986 Jan; 28(704):1-2. PubMed ID: 3941654 [No Abstract] [Full Text] [Related]
29. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
30. Substituting generic drugs: state roles. Cauchi R NCSL Legisbrief; 2009; 17(25):1-2. PubMed ID: 19526654 [No Abstract] [Full Text] [Related]
31. Implications of the Lannett and Pharmadyne decisions. Vetrano AJ Am J Hosp Pharm; 1980 Apr; 37(4):537-40. PubMed ID: 7377217 [TBL] [Abstract][Full Text] [Related]
32. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
33. FDA action spurs change in groups' drug programs. Perry PA Hosp Mater Manage; 1989 Nov; 14(11):1, 13-4. PubMed ID: 10295911 [No Abstract] [Full Text] [Related]
35. Generic vs. brand name drugs--patients, pharmacists, physicians: caught in the middle. Felch WC Internist; 1979 May; 20(4):3-5. PubMed ID: 10242131 [No Abstract] [Full Text] [Related]
36. FDA issues requirement for retaining drug samples. Oncology (Williston Park); 1991 May; 5(5):176. PubMed ID: 1832001 [No Abstract] [Full Text] [Related]
37. Regulatory evaluation of biotechnology drugs: current trends in the United States. Sobel S Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148 [No Abstract] [Full Text] [Related]
38. Additional generics on the market. FDA Drug Bull; 1986 Nov; 16(2):14-5. PubMed ID: 3817341 [No Abstract] [Full Text] [Related]
39. Therapeutic equivalency of drugs. Fact or fiction? Stetler CJ Med Ann Dist Columbia; 1969 Jun; 38(6):297-300. PubMed ID: 5257886 [No Abstract] [Full Text] [Related]
40. Lessons learned from good manufacturing practice noncompliance. Peskoe MP Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]